Manufacturer Interest in U.S./EU MRA Remains Unknown
This article was originally published in The Silver Sheet
Executive Summary
THE U.S./EUROPEAN MUTUAL RECOGNITION AGREEMENT nears the half-way point of its three-year "transition" with uncertainty as to whether medical device manufacturers will take advantage of the agreement's third-party inspection or 510(k) review options. The agency estimates 12 to 15% of device firms are agreeing to participate in the joint audit training program for European-based third-party inspectors who will be allowed to perform FDA audits in Europe once the MRA enters its operational phase in December 2001. Industry proponents of the MRA look forward to the possibility of having both FDA and European Union device inspection requirements covered during a single audit WARNING LETTERS: Corrective actions to address LifePak 500 component failures inadequate, FDA tells Medtronic Physio-Control; Tripath Imaging AutoCyte PREP promotional claims require agency approval
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.